APhA, in a formal comment letter, reiterated its concerns with FDA's list of drugs that present demonstrable difficulties for compounding. APhA's concerns include the agency's decision to identify ...

seeking to put the drug on an FDA list of compounds deemed to be difficult to compound, but has so far been unsuccessful. The new move comes as Eli Lilly has also taken action against compounders ...

Under US law, compounding pharmacies can make and sell patent-protected drugs that are on the FDA's shortages list in limited amounts, and have been reaping the rewards of supplying versions of ...

To address this issue, the signatories urge FDA to take the following action: Enforce Existing Regulations: Ensure that compounding pharmacies adhere to federal regulations by discontinuing the ...

The FDA says compounding pharmacies, which make similar versions of name-brand drugs like Ozempic and Wegovy, will no longer be allowed to sell them after the end of April and May. In 2022 ...

compounding pharmacy plaintiffs argued that the FDA arbitrarily removed Eli Lilly’s weight loss drug tirzepatide from the drug shortage list. The compounding pharmacies sought a preliminary ...

INDIANAPOLIS – The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs were taken off the FDA’s shortage list. Hundreds of ...